Retatrutide, from Soma Pharmaceuticals , represents a exciting breakthrough in body control . This unique compound combines GLP-1 receptor agonist function with gut-derived receptor engagement, indicating impressive potential in clinical studies for metabolic loss . Experts believe this treatment